Navigation Links
MultiVu Video Feed: WELCHOL (R) (COLESEVELAM HCL) RECEIVES FDA APPROVAL FOR GLUCOSE CONTROL IN ADULTS WITH TYPE 2 DIABETES MELITUS
Date:1/18/2008

Daiichi Sankyo, Inc. announced today that the United States Food and Drug Administration (FDA) has approved WelChol(R) (colesevelam HCl) Tablets as the first LDL cholesterol lowering medication also indicated for improving glycemic control in adults with type 2 diabetes mellitus (DM) in combination with metformin, sulfonylureas, or insulin, when these agents are used alone or in combination with other anti-diabetic agents.

The ADA estimates that 20.8 million people in the United States have diabetes and more than 90% of these have type 2 diabetes. People with diabetes face significantly higher risk of developing cardiovascular disease. It is estimated that approximately half of all Americans have elevated blood cholesterol levels that can negatively impact their health and quality of life. According to a recent Harris Interactive Survey, approximately 29% of adults previously diagnosed with hypercholesterolemia have also been diagnosed with diabetes. Given the prevalence of diabetes and high LDL cholesterol, a medication that can help lower both A1C and LDL cholesterol can be beneficial for many patients. Welchol is a new option that addresses these two chronic health conditions and provides physicians with a different therapeutic approach for treating patients with type 2 diabetes.
For more information, please visit http://www.dsus.com.

SATELLITE FEED:

Friday, January 18th, 2008

6:30 PM - 6:45 PM ET

Galaxy 25

C-Band

Transponder 14

Downlink Freq. 3980 Horizontal

Preview and access this video on Pathfire DMG: Slug # 29711

Search within the PR Newswire or MultiVu section by story ID # 29711 or by headline

For technical assistance call Pathfire Customer Care at 1-888-345-0489 or e-mail support@pathfire.com

NEWS: WelChol Receives FDA Approval To Reduce Blood Glucose in Adults with Type 2 Diabetes

FORMAT: B-roll and Soundbites.

ADDITIONAL RESOURCES: Video, contact information and more available at: http://www.prnewswire.com/broadcast/29711/press.html

SOUNDBITES:

* Dr. Ronald B. Goldberg, Professor of Medicine and Professor,

Biochemistry and Molecular Biology at the University of Miami and the

Associate Director of the Diabetes Research Institute

B-ROLL INCLUDES:

* Doctor/Patient footage

* Patient lifestyle & footage

* Product shots/manufacturing footage

* Daiichi Sankyo exteriors

VIDEO PROVIDED BY: Daiichi Sankyo

Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3


'/>"/>
SOURCE Daiichi Sankyo
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Photo: MultiVu Promotes George DeTorres to Divisional Vice President for the MultiVu Healthcare Team
2. MultiVu Video Feed: NEW SURVEY FINDS THAT HALF OF CAREGIVERS SPEND 10 PERCENT OF THEIR INCOME CARING FOR AN OLDER LOVED ONE
3. MultiVu Video Feed: STARLIGHT STARBRIGHT UNVEILS GET FIT, GET RIGHT A PROGRAM TO PREVENT TYPE 2 DIABETES AND WEIGHT-RELATED CONDITIONS IN TEENS
4. MultiVu Video Feed: Parents of Kids With Infectious Diseases Sounds Alarm About the Dangers of Pertussis With "Silence the Sounds of Pertussis" Campaign
5. MultiVu Video Feed: FDA Approves DORIBAX(TM) (doripenem for injection) for the Treatment of Complicated Intra-abdominal and Complicated Urinary Tract Infections
6. MultiVu Video Feed: PUBLIC HEALTH EXPERTS CONVENE TO DISCUSS THE TREATMENT AND PREVENTION OF RABIES
7. VIDEO from Medialink and The Leukemia & Lymphoma Society: Saving Lives One Mile at a Time
8. VIDEO from Medialink and Stryker: New Alternative to Hip Replacement Surgery
9. InfoLogix Featured in FOX Business News Interview on Reducing Healthcare Medication Errors - Video Available Online
10. VIDEO from Medialink and Revolution Health: RevolutionHealth.com Launches Resolutions 2.0
11. VIDEO from Medialink and GlaxoSmithKline: Really Think You Can Lose 30 Pounds in 30 Days?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , ... February 23, 2017 , ... ... thought leadership , media relations, content marketing, social media management, corporate communications, SEO ... already in the state and in nearby New Hampshire, Massachusetts and Canada, Rosica ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing LLC announces ... and explore the world from different perspectives. By providing a place for people ... understanding, increase empathy, and find greater happiness. , "Our approach to structuring ...
(Date:2/23/2017)... ... 23, 2017 , ... The Center for Autism and Related ... Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The ... see films in an environment that accommodates their unique needs. , Launched in ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that ... of CM-AT in children aged 3-8 with Autism, is now enrolling at three new ... children across the United States. , “There are currently no approved drugs that ...
(Date:2/22/2017)... York (PRWEB) , ... February 22, 2017 , ... ... entrance and lobby of a new healthcare contact center in Georgia, PENETRON Specialty ... One of the nation’s largest healthcare systems recently invested $51 million to purchase ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Feb. 23, 2017   SeraCare Life Sciences ... in vitro diagnostics manufacturers and clinical laboratories, is ... Implementation of NGS-Based Tests" to be hosted by ... at 11am Eastern Standard Time (US). ... the need for improved performance and global standardization ...
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... a clinical-stage oncology drug development company, announces that ... and Drug Administration (FDA) authorizing the initiation a ... therapeutic treatment for pancreatic cancer. MVT-1075 ( 177 ... radioimmunotherapy (RIT). MabVax plans to initiate the phase ...
(Date:2/23/2017)... This report analyzes analyzes the worldwide markets for Wound Debridement Products ... the US, Canada , Japan ... , Latin America , and Rest ... period 2015 through 2022. Also, a six-year historic analysis is ... from primary and secondary research. Company profiles are primarily based ...
Breaking Medicine Technology: